This action plan is intended for senior-level decision-makers in ministries of health, malaria
programme managers, entomologists, and epidemiologists working on malaria and other vectorborne diseases programmes. It is also intended for decision-makers and technical and advocacy
staff at other orga...nizations and stakeholders involved in public health, malaria control and
elimination, and urban and rural development.
more
This manual and its Excel tool are under revision. The revised edition will be published soon.
Este manual y la herramienta de Excel que lo acompaña se encuentran en proceso de revisión. La edición revisada se publicará próximamente.
Website last accessed on 22.05.2023
Leishmaniasis refers to a diverse group of diseases caused by single-celled parasites called Leishmania. About 12 million people are infected at any one time, causing up to 40,000 deaths annually.
The VALIDATE Network - Vaccine development for complex intra...cellular neglected pathogens
more
This document outlines PAHO’s regional priorities for the year 2023 to sustain and scale up health emergency and humanitarian assistance in the Americas, with a focus on five priority countries currently facing a prolonged humanitarian crisis and recovering from recent acute emergencies: Colombia,... El Salvador, Guatemala, Haiti, and Venezuela (Bolivarian Republic of). These goals align with and build on the World Health Organization’s Global Health Emergency Appeal for 2023, its principles, priorities, and strategies.
more
Only 8,730 asylum applications were registered in the EU+ in April, the lowest since at least 2008, and a massive 87% decrease from pre-COVID-19 levels in January and February.
The European Asylum Support Office (EASO) has released a special report which shows that the COVID-19 related travel restr...ictions and national health measures which were imposed during the past few months led to a dramatic cut in asylum applications in Europe.
more
The Best practice portal is a resource for professionals, policymakers and researchers in the drugs field. We provide information on the available evidence on drug-related prevention, treatment and harm reduction, focusing on the European context. The evidence is compiled following an explicit metho...dological process.
more
This publication represents a key step forward in translating Control of the leishmaniases (WHO Technical Report Series, No. 949) into a more practical tool for health personnel directly involved in the case management of cutaneous leishmaniasis. With this manual, countries will have, for the first ...time, standardized diagnosis and treatment protocols, case definitions and indicators to enable them to easily track progress on cutaneous leishmaniasis case management across the Region. It will provide support to professionals in charge of cutaneous leishmaniasis, in order to alleviate the suffering of affected populations from this appalling disfiguring and stigmatizing neglected tropical disease.
more
The Information, education and communication (IEC) activities, with the development of contextualized activities for various actors and scenarios about preventative measures and surveillance tools, are essential to increase awareness, reduce biomedical and psychosocial barriers to accessing diagnosi...s and care; keep the maximum number of actors involved; and reach the affected population, including family, friends and society in general.
more
This statistical overview has been prepared on the occasion of the European Institute for
Gender Equality (EIGE) study on FGM in the European Union and Croatia. Little is known
about FGM in the European Union in general, and this statement holds true about FGM
and asylum more specifically. In lig...ht of the recognized need for country- and community-
tailored responses, this study provides some of the statistical evidence needed to
advance the discussion on the necessary policies and tools to address the specific
vulnerabilities of female asylum-seekers with FGM in the asylum system on the one hand,
and of refugee girls and women living with FGM and integrating in EU Member States on
the other hand
more
Leishmaniasis is a vector-borne disease with a wide variety of parasite species, reservoirs, and vectors involved in transmission. It is caused by different species of the protozoa Leishmania and is transmitted to animals and humans through a bite of insects in the Psychodidae family. Its presence i...s directly linked to poverty, but social, environmental, and climatalogic factors directly influence the disease's epidemiology.
more
Since 2000, concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important achievements in the control of human African trypan...osomiasis (HAT). As a consequence, the disease was targeted for elimination as a public health problem by 2020. The Sixty-sixth World Health Assembly endorsed this goal in resolution WHA66.12 on neglected tropical diseases, adopted in 2013.
National sleeping sickness control programmes (NSSCPs) are core to progressing control of the disease and in adapting to the different epidemiological situations. The involvement of different partners, as well as the support and trust of long-term donors, has been crucial for the achievements.
more
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs aiming to contain the disease had ground to a halt, given previous success against HAT and the competing priorities associat...ed with other medical crises ravaging the continent. A series of dedicated interventions and the introduction of innovative routes to develop drugs, involving Product Development Partnerships, has led to a dramatic turnaround in the fight against HAT caused by Trypanosoma brucei gambiense. The World Health Organization have been able to optimize the use of existing tools to monitor and intervene in the disease. A promising new oral medication for stage 1 HAT, pafuramidine maleate, ultimately failed due to unforeseen toxicity issues. However, the clinical trials for this compound demonstrated the possibility of conducting such trials in the resource-poor settings of rural Africa.
more
Treatment of second-stage gambiense human African trypanosomiasis relied on toxicarsenic-based derivatives for over 50 years. The availability and subsequent use of eflornithine,initially in monotherapy and more recently in combination with nifurtimox (NECT), has drasticallyimproved the pro...gnosis of treated patients. However, NECT logistic and nursing requirementsremain obstacles to its deployment and use in peripheral health structures in rural sub-SaharanAfrica. Two oral compounds, fexinidazole and SCYX-7158, are currently in clinical development.The main scope of this article is to discuss the potential impact of new oral therapies to improvediagnosis-treatment algorithms and patients’access to treatment, and to contribute to reach theobjectives of the recently launched gambiense humanAfrican trypanosomiasis elimination program
more
Information for the General Public
Epidemiological Update
Dengue
7 February 2020
Situation summary
In the Region of the Americas, between epidemiological week (EW) 1 and EW 521 of 2019, a total of 3,139,335 cases of dengue have been reported (321.58 cases per 100,000 population), including 1,538 deaths. Of the total cases, 1,367,...353 (43.6%) were laboratory-confirmed and 28,169 (0.9%) were classified as severe dengue. The case-fatality rate was 0.049%.
more
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more
Chagas disease, or American trypanosomiasis, is a condition that causes gradual organ damage. Without treatment, it can be fatal.
This article explains where the T. cruzi parasite is most common and how it can spread. It also outlines the symptoms of Chagas disease and the treatment options avail...able.
more
The Strategy aims to protect and improve the well-being
of society and of the individual, to protect and promote
public health, to offer a high level of security and well-being
for the general public and to increase health literacy. The
Strategy takes an evidence-based, integrated, balanced and
...
multidisciplinary approach to the drugs phenomenon at
national, EU and international level. It also incorporates a
gender equality and health equity perspective.
more
Esta hoja informativa destaca la relación entre el consumo de alcohol y la COVID-19. El alcohol se utiliza a menudo para la socialización y por algunas personas para hacer frente a las emociones difíciles como la ansiedad, el miedo, la depresión, el aburrimiento y la incertidumbre, todo lo cual ...aumentó durante la pandemia de COVID-19, con el consiguiente incremento en el consumo de alcohol, especialmente en quienes ya bebían en exceso.
more